These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 29040782)

  • 21. EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing.
    Francis JM; Zhang CZ; Maire CL; Jung J; Manzo VE; Adalsteinsson VA; Homer H; Haidar S; Blumenstiel B; Pedamallu CS; Ligon AH; Love JC; Meyerson M; Ligon KL
    Cancer Discov; 2014 Aug; 4(8):956-71. PubMed ID: 24893890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EGF/EGFR upregulates and cooperates with Netrin-4 to protect glioblastoma cells from DNA damage-induced senescence.
    Li L; Huang Y; Gao Y; Shi T; Xu Y; Li H; Hyytiäinen M; Keski-Oja J; Jiang Q; Hu Y; Du Z
    BMC Cancer; 2018 Dec; 18(1):1215. PubMed ID: 30514230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma.
    Lassman AB; Aldape KD; Ansell PJ; Bain E; Curran WJ; Eoli M; French PJ; Kinoshita M; Looman J; Mehta M; Muragaki Y; Narita Y; Ocampo C; Roberts-Rapp L; Song M; Vogelbaum MA; Walenkamp AME; Wang TJC; Zhang P; van den Bent MJ
    J Neurooncol; 2019 Aug; 144(1):205-210. PubMed ID: 31273577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
    Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
    Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidermal growth factor receptor: a re-emerging target in glioblastoma.
    Hegi ME; Rajakannu P; Weller M
    Curr Opin Neurol; 2012 Dec; 25(6):774-9. PubMed ID: 23007009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of molecular genetic alterations in GBMs highlights a distinctive molecular profile in young adults.
    Jha P; Suri V; Singh G; Jha P; Purkait S; Pathak P; Sharma V; Sharma MC; Suri A; Gupta D; Mahapatra AK; Sarkar C
    Diagn Mol Pathol; 2011 Dec; 20(4):225-32. PubMed ID: 22089350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Near-infrared photoimmunotherapy targeting EGFR-Shedding new light on glioblastoma treatment.
    Burley TA; Mączyńska J; Shah A; Szopa W; Harrington KJ; Boult JKR; Mrozek-Wilczkiewicz A; Vinci M; Bamber JC; Kaspera W; Kramer-Marek G
    Int J Cancer; 2018 Jun; 142(11):2363-2374. PubMed ID: 29313975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges.
    Reardon DA; Wen PY; Mellinghoff IK
    Neuro Oncol; 2014 Oct; 16 Suppl 8(Suppl 8):viii7-13. PubMed ID: 25342602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma.
    Li H; Wang Y; Su F; Li J; Gong P
    Int J Clin Exp Pathol; 2015; 8(5):5577-83. PubMed ID: 26191267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EGFR and PDGFRA co-expression and heterodimerization in glioblastoma tumor sphere lines.
    Chakravarty D; Pedraza AM; Cotari J; Liu AH; Punko D; Kokroo A; Huse JT; Altan-Bonnet G; Brennan CW
    Sci Rep; 2017 Aug; 7(1):9043. PubMed ID: 28831081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The concomitant gene alterations impact the therapeutic efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutation].
    Li JM; Hu J; Bai CX; Zhang Y; Xu XB; Wang XD; Ding N
    Zhonghua Jie He He Hu Xi Za Zhi; 2018 Oct; 41(10):778-782. PubMed ID: 30347549
    [No Abstract]   [Full Text] [Related]  

  • 32. Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy.
    Tanaka S; Luk S; Kiyokawa J; Onozato ML; Iafrate AJ; Shah K; Martuza RL; Rabkin SD; Batchelor TT; Cahill DP; Chi AS; Wakimoto H
    Sci Rep; 2019 Jan; 9(1):139. PubMed ID: 30644426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Small cell architecture--a histological equivalent of EGFR amplification in glioblastoma multiforme?
    Burger PC; Pearl DK; Aldape K; Yates AJ; Scheithauer BW; Passe SM; Jenkins RB; James CD
    J Neuropathol Exp Neurol; 2001 Nov; 60(11):1099-104. PubMed ID: 11706939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
    Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
    BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EGFR-targeted therapies in the post-genomic era.
    Xu MJ; Johnson DE; Grandis JR
    Cancer Metastasis Rev; 2017 Sep; 36(3):463-473. PubMed ID: 28866730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High level EGFR amplification in a newly established glioblastoma cell line 170-MG-BA.
    MacLeod RAF; Schneider B; Sivakova I; Nagel S; Dirks WG; Mraz P; Kubikova E; Perzelova A
    Neoplasma; 2019 Jan; 66(1):109-117. PubMed ID: 30509096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dacomitinib: an investigational drug for the treatment of glioblastoma.
    Sepúlveda JM; Sánchez-Gómez P; Vaz Salgado MÁ; Gargini R; Balañá C
    Expert Opin Investig Drugs; 2018 Oct; 27(10):823-829. PubMed ID: 30247945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A wide spectrum of EGFR mutations in glioblastoma is detected by a single clinical oncology targeted next-generation sequencing panel.
    Cimino PJ; Bredemeyer A; Abel HJ; Duncavage EJ
    Exp Mol Pathol; 2015 Jun; 98(3):568-73. PubMed ID: 25910966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.
    Juchum M; Günther M; Laufer SA
    Drug Resist Updat; 2015 May; 20():12-28. PubMed ID: 26021435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prognostic implication of alterations in epidermal growth factor receptor and MGMT in glioblastoma].
    Zhang LY; Ge HJ; Wang LM; Zhao LH; Liu L; Zhang DJ; Cai YN; Lu DH; Piao YS
    Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):186-191. PubMed ID: 30831643
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.